From the

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To.

BANFORD, Paul, Clifford Marks & Clerk 43 Park Place Leeds LS1 2RY GRANDE BRETAGNE M & C 2 & Dec 2003 Legas Office

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

IMPORTANT NOTIFICATION

Date of mailing (day/month/year)

18.12.2003

Applicant's or agent's file reference PCT/P89103PWO

international filing date (dav/month/year)

Priority date (day/month/year)

International application No. PCT/GB03/01623

15.04.2003

17.04.2002

Applicant

THE UNIVERSITY OF NEWCASTLE et al.

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 Authorized Officer

Zoglauer, H

Tel. +49 89 2399-8051





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCT/P89103PWO	FOR FURTHER ACTION	
International application No. PCT/GB03/01623	International filing date (day/n 15.04.2003	Priority date (day/month/year) 17.04.2002
International Patent Classification (IPC C12N9/12	or both national classification and IP	
Applicant THE UNIVERSITY OF NEWCA		
This international preliminary Authority and is transmitted to	examination report has been pre the applicant according to Articl	pared by this International Preliminary Examining e 36.
2. This REPORT consists of a to	otal of 5 sheets, including this co	ver sheet.
been amended and are	mpanied by ANNEXES, i.e. sheet the basis for this report and/or sh ction 607 of the Administrative In	ts of the description, claims and/or drawings which have neets containing rectifications made before this Authority structions under the PCT).
These annexes consist of a to	otal of sheets.	•
3. This report contains indication Basis of the opinion	ns relating to the following items:	
II □ Priority III □ Non-establishmen	t of opinion with regard to novelty	v, inventive step and industrial applicability
IV Lack of unity of in	/ention	
	ent under Rule 66.2(a)(ii) with reg anations supporting such stateme	gard to noveity, inventive step or industrial applicability; ent
VI 🗆 Certain document	s cited	
VII Certain defects in	the international application	
VIII Certain observation	ns on the international application	n .
Date of submission of the demand	Date	of completion of this report
22.10.2003	18.1	12.2003
Name and mailing address of the international preliminary examining authority:	ational Auth	orized Officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 5 Fax: +49 89 2399 - 4465	523656 epmu d	phone No. +49 89 2399-7493

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/GB03/01623

	_	•				
1.	Bas	SIS	OT 1	tne	rei	oort

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Des	scription, Pages	·
	1-2	5	as originally filed
	Cla	ims, Numbers	
	1-2	6	as originally filed
	Dra	wings, Sheets	
	1/7-	7/7	as originally filed
Sec	que	nce listing part of t	ne description, pages:
1-4	3, 1	filed with the letter of	12.6.03,
2.	Witl lang	n regard to the lang u guage in which the in	age, all the elements marked above were available or furnished to this Authority in the ternational application was filed, unless otherwise indicated under this item.
	The	se elements were av	railable or furnished to this Authority in the following language: , which is:
		the language of a tra	anslation furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of pub	lication of the international application (under Rule 48.3(b)).
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under 3).
3.	Witl inte	n regard to any nucl e rnational preliminary	eotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:
		contained in the inte	ernational application in written form.
		filed together with th	ne international application in computer readable form.
	\boxtimes	furnished subseque	ntly to this Authority in written form.
	\boxtimes	furnished subseque	ntly to this Authority in computer readable form.
	☒	The statement that to in the international a	the subsequently furnished written sequence listing does not go beyond the disclosure application as filed has been furnished.
	☒	The statement that the listing has been furn	the information recorded in computer readable form is identical to the written sequence iished.
4.	The	amendments have r	resulted in the cancellation of:
		the description,	pages:
ļ		the claims,	Nos.:
ļ		the drawings,	sheets:



International application No.

PCT/GB03/01623

5. 🗆	This report has been established as if (some of) the amendments had not been made, since they have
•	been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

No:

Yes: Claims Claims 1-26

Inventive step (IS)

Yes: Claims

1-26

Claims No:

Industrial applicability (IA)

Yes: Claims

1-26

Claims No:

2. Citations and explanations

see separate sheet

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents

- D1: GREAGG M A ET AL: 'A read-ahead function in archaeal DNA polymerases detects promutagenic template-strand uracil.' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 3 AUG 1999, vol. 96, no. 16, 3 August 1999 (1999-08-03), pages 9045-9050, XP002250142 ISSN: 0027-8424
- D2: EVANS S J ET AL: 'Improving dideoxynucleotide-triphosphate utilisation by the hyper-thermophilic DNA polymerase from the archaeon Pyrococcus furiosus.' NUCLEIC ACIDS RESEARCH. ENGLAND 1 MAR 2000, vol. 28, no. 5, 1 March 2000 (2000-03-01), pages 1059-1066, XP002164138 ISSN: 1362-4962
- D3: FOGG MARK J ET AL: 'Structural basis for uracil recognition by archaeal family B DNA polymerases.' NATURE STRUCTURAL BIOLOGY. UNITED STATES DEC 2002, vol. 9, no. 12, December 2002 (2002-12), pages 922-927, XP002250141 ISSN: 1072-8368

Document D3 was published after the priority date but before the filing date of the present application. It does, therefore, not constitute part of the state of the art in the meaning of Rule 64(1)(b) PCT. At the moment the validity of the priority claimed by the present application cannot be checked as the priority document is not yet available. However, if it later turns out that the priority of the present application has not been correctly claimed, D3 will become of relevance for the novelty and for the inventive step of the claimed subject-matter.

Novelty and Inventive step (Art. 33(2), Art. 33(3) PCT)

The subject-matter of claims 1-26 can be considered novel and inventive for the following reasons.

The wild-type nucleotide and amino acid sequences of the archeal DNA polymerases mutated in the application were known as well as some of their crystal structures (see,

INTERNATIONAL PRELIMINARY International application No. PCT/GB03/01623 EXAMINATION REPORT - SEPARATE SHEET

for example, references cited in the description, page 17).

However, no suggestion on how to improve these polymerases by decreasing their affinity for uracil can be found in the prior art. The problems linked to the mutagenic potential of uracil had been recognized in the prior art (see e.g. D1), but no solution had been proposed. The DNA polymerase of *P. furiosus* had been modified to improve its utilization of ddNTPs (see D2), but the residues mutated as well as the purpose of these mutations are different from those described in the application.

The applicant's attention is drawn to the fact that claims 1-4 contain no reference to the sequences of the polymerases and are, therefore . considered unclear (Art. 6 PCT).